Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.40 1.22% 116.60 116.80 117.20 117.20 114.00 116.00 1,033,826 16:35:07
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 186.1 17.5 6.7 1,239

Ip Share Discussion Threads

Showing 2401 to 2423 of 2550 messages
Chat Pages: 102  101  100  99  98  97  96  95  94  93  92  91  Older
DateSubjectAuthorDiscuss
13/5/2021
15:09
Webinar today highlighted Waveoptics working with several big tech firms to bring AR products to market. Difficult to find much public info on the competing waveguide companies but has the potential to be another big winner in the portfolio given the sizeable holding.
wetpantz
13/5/2021
13:41
To everyone their own approach to investing. But for a real insight into quantitative approaches to investing it is worth reading up on the views of J Doyne Farmer. An early expert in chaotic systems, he made a fortune exploiting small short term inefficiencies in stock markets and then returned to academia as a maths professor at Oxford. His explanations of why linear analyses are useless (and charts are linear) as opposed to non-linear analysis is informative and comes from an expert background. My other problem with charts is that any system which is easy carries no lasting advantage - because others can see the same data and do the same analysis. It is simply another variant of the old investor question - does your product have a lasting advantage with a high entry barrier. Charts do not.
wba1
13/5/2021
11:06
eeza, Most have their own style and influences! We'll find out in due course where support lies. Added a few to the sipp near the lows today. Once Oxford Nanopore have their London Calling Event finished next week, we should start to see some more flotation activity.
bamboo2
13/5/2021
10:11
Lara Lewington online now. Just getting going with Technology Trailblazers Webinar. There are live Q&A later.
bamboo2
13/5/2021
10:02
Thank you, bamboo. My charting not as good as yours.
eeza
13/5/2021
09:59
Hi eeza, Re H&S, I am working on the daily scale. I have left armpit 25/3/2021[118.4], right at 6/5/2021[123.2] Based on Bulkowski stats... Head height is 14, target is 55% of hh. Measured from neckline break 123-7.7 = 115.3 Adjacent historical support approx 113.5-114.5 Should be about there now, but my chart is showing a turn more likely tomorrow.
bamboo2
13/5/2021
09:53
1p of the drop accounted for by being XD for 1p today. Payment on 16 June.
eeza
13/5/2021
09:44
H & S looks to be in play now. Target 105p, bamboo?
eeza
12/5/2021
10:01
Charting is an optinal input, not a religion. Useful extra level of input to help make decisions. Once I started to take price vs time and volume vs time into account (along with some maths) my results improved. If it doesn't work for others, that's OK. I need it to help offer an extra dimension.
p1nkfish
12/5/2021
09:28
Always best to hit the apex on a turn. Think we might to talking about different things but that's my view.
scubadiverr
12/5/2021
09:18
Pierre, I used to have exactly the same view on charts as you and I would regularly filter those presenting chart based ideas because it was hard to understand the terminology/jargon. Things changed after I started experimenting with patterns and apex based turns. Now they work really well for me. Obviously we are not charting randomly, and other factors are used to screen for charts of interest. They are just another useful tool.
bamboo2
12/5/2021
09:06
Chart - believers vs non believers = Brexit Remain vs Leave. Opinions, fiercely held.
eeza
12/5/2021
08:47
bb2, noticed the price action in IPO & GROW? Both bouncing off sopport today. I'm thinking there is another leg down due over Summer, not bottomed yet - just an inkling.
p1nkfish
12/5/2021
08:09
eeza, thanks for confirmation. Most aspects I am clear about, but Ex/d and ex-rights dates always leave me feeling slightly uncertain!
bamboo2
12/5/2021
07:55
smose, The scrip price will be set 19/5/21. So you can calculate how many scrip shares you will get, if you choose them. There is no dealing charge or stamp duty, so if you want to increase your holding, it's a good thing. The scrip issue will result in a small dilution, depending on how many choose it, so some may also take this into account. Benefit to the co is that the cash balance [and therefore NAV] remains higher. You have until 28/5/21 to decide on taking the scrip or cash, so there may be a small arb on offer. Payment is 16/6/21 HL should give you a choice once the share has gone ex/d.
bamboo2
12/5/2021
07:49
XD is effective at 1630.01 today. i.e you have to be holding at close today to be eligible for the Div. You can sell at open tomorrow (0800 Thurs) and still receive Div.
eeza
12/5/2021
07:44
@bamboo2 How do we opt for the scrip dividend? My IPO shares are in HL
smose
12/5/2021
07:36
Share goes xd at eod today. Looking at divi rns there could be a two day settlement, so I am unsure of the day you can sell, still retaining the entitlement to the divi. Could be Thursday 13 May or Friday 14 May. Anyone able to confirm? The scrip alternative is interesting because it avoids a dealing charge, and .5% stamp duty, so currently I am going to take the scrip.
bamboo2
12/5/2021
07:29
eeza, We already had small one which hit tp today. There is also a bear flag which is the rh shoulder of this small h&s, which has its tp at 118.4 I can see what you mean about a possible larger formation, although there is a similar shape further back down the chart end of December to January 2021, that didn't shape up. I have current NAV approaching 140, and hope that this discount will be noticed by the market.
bamboo2
11/5/2021
21:12
Only the most basic, bamboo. But always useful to see where support and resistance are likely to be encountered. Fundies might change - but human nature doesn't, and the battles are displayed in the chart. Possibly H & S forming?
eeza
11/5/2021
20:49
eeza, Good charting! I thought we would find support adjacent to the prior gap, but a visit to the lower end of the support zone was always possible. Do you use TA often? eeza - 05 May 2021 - 17:21:01 - 1077 Chart suggests it's heading to 120p support.
bamboo2
11/5/2021
20:43
Court of Appeals for the Federal Circuit, US, upholds jury decision to invalidate certain PacBio patents Tue 11th May 2021 Today the Court of Appeals for the Federal Circuit issued a unanimous Precedential Opinion and Judgment affirming the jury’s March 2020 verdict in the PacBio v. Oxford Nanopore case, that invalidated a number of PacBio patents. This has been a long running dispute in which Oxford Nanopore has repeatedly prevailed. In 2018, Oxford Nanopore was found by the ITC not to infringe other patents wrongly asserted against it by PacBio. That ruling was also affirmed by the Federal Circuit. Oxford Nanopore is pleased with this outcome, which it anticipates effectively ends a series of frivolous disputes perpetrated by PacBio. Oxford Nanopore continues to innovate and bring high-performance, disruptive sequencing products to a global community of scientists. =========================================== Some history leading to Pacb's appeal... Wed 18th March 2020 After more than one week of evidence, a federal jury in Delaware found in favour of Oxford Nanopore and invalidated all four patents asserted by Pacific Biosciences ("PacBio") in this litigation. During the trial, the jury heard evidence that PacBio had never performed nanopore sequencing, before or after they filed patents that allegedly cover nanopore sequencing. Despite all of the early work by the established innovators of nanopore sequencing such as David Deamer, Dan Branton, George Church, Hagan Bayley and Mark Akeson, as well as Oxford Nanopore’s extensive in-house innovation since 2005, PacBio wrongly claimed it was one of the key innovators of the technology. This outcome follows positive outcomes for Oxford Nanopore in previous proceedings: a summary determination of noninfringement by the U.S. International Trade Commission, and invalidation of one of PacBio’s asserted patents by the European Patent Office. Dr Gordon Sanghera, CEO of Oxford Nanopore, said: “We are pleased that the jury recognized that it is Oxford Nanopore, with the help of our collaborators across the globe and as part of the thriving nanopore community of users, who are the true innovators in the field of nanopore sequencing.” Dr. Sanghera added “This was the latest in a long line of nefarious attempts to exclude Oxford Nanopore from the market. We will continue to deliver innovative sequencing technology to our customers, who are using the technology to make a profound, positive impact on society. We will continue to fight attempts to ‘tangle up’ our innovation.” ======================================= Wed 17th July 2019 Oxford Nanopore has prevailed once again following the decision yesterday by the European Patent Office (EPO) to revoke a second PacBio European Patent, EP3170904. This decision is consistent with that of an earlier EPO decision revoking PacBio European Patent EP3045542, as well as rulings from the ITC and US Court of Appeal that the claims of the respective patents were not entitled to a broad interpretation of the term ‘single molecule sequencing’. ======================================= Tue 12th February 2019 - Decision defeats attempts by PacBio to prevent Oxford Nanopore from selling its technology in the US - Oxford Nanopore announces that the US Court of Appeals for the Federal Circuit today upheld the decision of the International Trade Commission (ITC) in favour of Oxford Nanopore. In a complaint previously filed by Pacific Biosciences, the ITC had previously ruled that the patents being asserted against Oxford Nanopore with claims directed towards a method of single molecule sequencing were limited to template-dependent synthesis. The decision was also consistent with a recent decision by the European Patent Office to revoke Pacific Biosciences’ patent EP3045542 with claims to a single molecule sequencing process. “Pacific Biosciences has not succeeded in its strategy to try to prevent us from selling our real-time, direct sequencing technology, that can provide a full range of solutions from field-based sequencing to terabases of ultra long reads in a lab,” said Gordon Sanghera, CEO. The court issued a Rule 36 judgement, which is a unanimous confirmance of the ITC findings.
bamboo2
10/5/2021
10:14
I really don't understand why the rank amateurs here, like Pierre, are desperately hanging on to IPO when there are other stronger alternatives like SUPP going cheap.
petethepict
Chat Pages: 102  101  100  99  98  97  96  95  94  93  92  91  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210623 18:23:25